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ABSTRACT
Background: Although caramiphen produces spinal anesthesia, caramiphen and carbetapentane have never been tested as infiltrative cutaneous analgesia. The aim of this study was to compare cutaneous analgesia of caramiphen and carbetapentane with bupivacaine and evaluated their central nervous system (CNS) and cardiovascular (CV) toxicity.
Methods:
After the blockade of cutaneous trunci muscle reflex with subcutaneous drug injections in rats, we evaluated the local anesthetic effect of carbetapentane and caramiphen on infiltrative cutaneous analgesia. Following continuous intravenous infusion of equipotent doses of bupivacaine, carbetapentane, caramiphen, and saline, we observed mean arterial blood pressure (MAP) and heart rate (HR) and monitored the onset time of seizure, apnea, and impending death.
Results: Carbetapentane and caramiphen acted like bupivacaine and elicited cutaneous analgesia in a dose-related fashion. On a 50% effective dose (ED 50 ) basis, the ranks of potencies were bupivacaine (1.78 [1.52 -2.07]) > carbetapentane (2.53 [2.38 -2.77]) > caramiphen (3.60 [3.41 -3 .99]) (P < 0.01). At equianalgesic doses (ED 25 , ED 50 , ED 75 ), the duration caused by carbetapentane or caramiphen was similar to that caused by bupivacaine. Under equipotent doses, the infusion time of carbetapentane or caramiphen required to cause seizure, apnea, and impending death was longer than that of bupivacaine (P < 0.05). The decline in MAP and HR was slower with carbetapentane or caramiphen when compared with bupivacaine (P < 0.01 for the differences) at equipotent doses.
Conclusions:
Carbetapentane and caramiphen were similar to bupivacaine at producing durations of cutaneous analgesia but were less likely than bupivacaine to induce CNS and CV toxicity. 4 In addition, caramiphen has been shown to have a local anesthetic effect on spinal anesthesia in rats. 5 The injections of local anesthetics are used for infiltration anesthesia of skin incision sites for laparoscopic surgery 6 and to provide postoperative pain relief after vaginal hysterectomy and inguinal hernia repair. 7 However, the technique is limited by the short duration of analgesia or anesthesia. 8 For this reason, bupivacaine is chosen for infiltration anesthesia because of its longer duration of effective analgesia. Recently, we showed that the long duration caused by caramiphen 5 
MATERIALS AND METHODS

Animals
Male Sprague-Dawley rats weighting 240-290g were obtained from the National Laboratory Animal Centre (Taipei, Taiwan), and then were housed in groups of three, with food and water freely available until the time of the study. The room temperature was controlled at 22℃ with approximately 50% humidity and a 12-h light/dark cycle 
Experimental protocols
The protocol was divided into two parts. In Part I, the cutaneous analgesic effect of different doses of bupivacaine (7. time to cause toxicity (seizures, apnea, and cardiac arrest), mean arterial blood pressure (MAP), and heart rate (HR) were evaluated after equipotent doses of the drugs (bupivacaine, carbetapentane, and caramiphen) were infused into the rat (n = 8 rats for each dose of each drug). Saline group (n = 8 rats) was used as a control.
Part I -Infiltrative cutaneous analgesia
Subcutaneous injection and neurobehavioral examinations
A trained examiner who was blinded to the experimental groups was responsible for handling of animals and behavioral examinations. Infiltrative cutaneous analgesia was evaluated by the cutaneous trunci muscle reflex (CTMR), characterized by the reflex movement of the skin over the back elicited by twitches of the lateral thoracospinal muscle in response to local dorsal cutaneous stimulation after drug injections. 16 In brief, the hair on the rats' dorsal surface of the thoracolumbar region (6 cm×10 cm) was mechanically shaved on the day before subcutaneous injection, and then each drug solved in 0.6 ml saline was injected subcutaneously using a 30-gauge needle into a naïve area of the shaved back of the un-anesthetized rats. 17, 18 The wheal within 2 cm diameter was marked with ink within 1 min after subcutaneous injection.
The cut end of an 18-gauge needle (a fresh regular bevel needle) was affixed to a von Frey filament (no. 15; Somedic Sales AB, Stockholm, Sweden) to produce a standardized noxious punctate mechanical stimulus (191 g) without making tissue damage.
After observing a rat's normal reaction to stimuli applied outside the wheal and on the contralateral side, we applied 6 stimuli at 6 different points within each wheal, with a frequency of 0.5 to 1 Hz, and scored the number to which the rat failed to react.
The magnitude of cutaneous analgesia was described as the percent of possible effect (% PE). For example, the absence of any response after 6 stimuli was defined as complete nociceptive block (100% PE), which was calculated as follows:
% PE = (number of stimuli that provoked no response/6) 100%
During the drug action, the maximum value of % PE was presented as percent of maximal possible effect (% MPE). Each duration (full recovery time) of drug action was defined as the time from drug injection (i.e., time=0) to full recovery of CTMR (no analgesic effect or 0% MPE).
19
The 50% effective dose (ED 50 ), ED 25 , and ED 75 After injecting subcutaneously the rats with 7 different doses of each drug (n = 8
for each dose of each drug), dose-response curves were constructed. Then the curves were fitted by SAS NLIN Procedures (SAS Institute Inc., Carey, NC, version 9.1), and the value of 50% effective dose (ED 50 ), defined as the dose that caused 50% cutaneous analgesia, was obtained. 20, 21 The ED 25 and ED 75 of drugs were obtained by the same SAS NLIN Procedures that were used to derive the ED 50. 22 Then the blockade duration caused by each drug was performed at equianalgesic doses (ED 25 , ED 50 , ED 75 ) (n = 8 rats for each dose of each drug). Furthermore, the area under curves (AUCs) of sensory blockades of drugs was estimated using Kinetica version 2.0.1 (InnaPhase Corporation, Philadelphia, PA).
Part II -Cardiovascular and neurological effects
On Day 1, rats were anesthetized with pentobarbital sodium (i.p.) at the dose of 50 mg·kg -1 and the right femoral artery and vein were cannulated with polyethylene catheters (PE-50), which were filled with heparin saline (35 U/mL). The free end of the catheter was threaded through a 18-gauge needle and then tunneled subcutaneously. The catheter was cut with 5 cm protruding from the skin at the midline in the posterior cervical area and sealed by heating it with a match and compressing it with a hemostat. 
Statistical Analysis
Values are presented as meanSEM or ED 50 values with 95% confidence interval (95% CI). The differences in baseline data, potencies (ED 50 s), %MPE, full recovery time, AUCs, and the time to cause toxicity between medications were evaluated using one-way analysis of variance (ANOVA) and then the pairwise
RESULTS
Carbetapentane and caramiphen, as well as bupivacaine produced dose-dependent cutaneous analgesia in rats (Figure 1) . The ED 50 s of drugs are shown in Table 1 . On the ED 50 basis, the relative potency of these three drugs was found to be bupivacaine > carbetapentane > caramiphen (P<0.01; Table 1 Table 2 ). At these given doses (Table 2) , there were no significant differences among these three drugs for the %MPE, full recovery time, and AUCs. Saline elicited no cutaneous analgesic effects. At equianalgesic doses (ED 25 , ED 50 , ED 75 ), the block duration caused by carbetapentane or caramiphen was similar to that caused by bupivacaine, a long-acting local anesthetic (Fig. 3) . All rats recovered completely after each subcutaneous injection.
The baseline data of body weight, MAP, and HR showed no significant differences among groups (Table 3) . At equipotent doses, the times required to cause seizure, respiratory arrest, and impending death were longer in the carbetapentane (P<0.05) or caramiphen (P<0.05) group than in the bupivacaine group (Figure 4 ).
There were no systemic toxicities in any of the animals in the saline group during the infusion period. The HR and MAP displayed a tendency to decrease before CV collapse ( Figure 5 ) in all drug groups. The declines in MAP and HR were slower in the carbetapentane (P<0.01) or caramiphen (P<0.01) group when compared with the bupivacaine group ( Figure 5 ). The rapidity of decline of the MAP and HR occurred in the following order: bupivacaine > carbetapentane > caramiphen ( Figure 5 ).
DISCUSSION
This study showed that carbetapentane and caramiphen displayed a dose-dependent local anesthetic effect on infiltrative cutaneous analgesia. The sensory/nociceptive block duration caused by carbetapentane or caramiphen was equal to that caused by bupivacaine, a long-acting local anesthetic. At equipotent doses, carbetapentane and caramiphen did not elicit systemic toxicity as quickly as bupivacaine.
Both carbetapentane and caramiphen have been known to treat coughing and related conditions clinically. 1, 4, 24, 25 Recently, we demonstrated that caramiphen has a local anesthetic effect on spinal anesthesia. 5 Infiltrative cutaneous anesthesia is an acceptable choice for management of surgical anesthesia and postoperative pain, because it is relatively free of side effects. 15 In this study, we showed that carbetapentane and caramiphen had a local anesthetic effect on infiltrative cutaneous analgesia in a dose-related fashion. Although the pharmacological mechanisms of carbetapentane and caramiphen are largely unclear, inhibiting Na + currents may be one of the principle mechanisms of carbetapentane and caramiphen to hold local anesthetic effects, which is worth testing in the next study.
Our previous studies showed that the spinal blockades with caramiphen at 4.62 μmole/kg 5 were similar to those with bupivacaine at 3.1 μmole/kg 10 on spinal anesthesia. In this recent experiment, bupivacaine has almost 1.4-and 2.0-fold greater potencies than carbetapentane and caramiphen as infiltrative cutaneous analgesia,
respectively. There appears to be a uniformity of the comparative potencies of caramiphen and bupivacaine with respect to cutaneous analgesia ( Figure 1 and Table   1 ) and spinal anesthesia. Furthermore, the sensory block duration of carbetapentane or caramiphen was similar to bupivacaine, a long-acting local anesthetic, on an equianalgesic basis (ED 25 , ED 50 , ED 75 ). These findings suggest that there may be a great potential for the use of carbetapentane and caramiphen as local anesthetics in the clinical setting, provided that the CNS and CV toxicity is investigated.
Accidental intravenous injection of local anesthetics may cause CNS and CV system toxicity and even result in death. 23, 26 Through an animal model of local anesthesia, we performed the local anesthetic effects of carbetapentane, caramiphen, and bupivacaine as infiltrative cutaneous analgesia to determine the equipotent analgesic doses of these drugs. At equipotent doses, we showed that infusion of carbetapentane or caramiphen produced a delayed onset of CNS and CV toxicity when compared with bupivacaine. However, the degrees of toxicities were the same once toxicity occurred (Figure 4) . Furthermore, we chose the animal model with the spontaneously breathing rats, a clinical scenario when local anesthesia is practiced on
humans. In addition, we also noticed that the declines in MAP and HR were longer with carbetapentane and caramiphen compared with bupivacaine. Overall, these results suggest that carbetapentane and caramiphen are less -toxic‖ and may feature a safer systemic toxicity profile than bupivacaine during continuous intravenous infusion.
In summary, our experiments reported that carbetapentane and caramiphen produced dose-dependent cutaneous analgesia and their block durations were similar to bupivacaine. Intravenous equipotent analgesic doses of carbetapentane and caramiphen are better tolerated to produce central nervous system and cardiovascular system toxicity than bupivacaine. The clinical relevance of these effects warrants further investigation. 
13.
Mazoit JX, Lambert C, Berdeaux A, Gerard JL, Froideveaux R.
Pharmacokinetics of bupivacaine after short and prolonged infusions in conscious dogs. Anesth Analg. 1988;67:961-966.
14.
Albright GA. Cardiac arrest following regional anesthesia with etidocaine or The %MPE, duration of drug action, AUCs (mean±SEM) between bupivacaine, carbetapentane, and caramiphen were not significantly different. There were no significant differences among the groups for these variables. MAP = mean arterial blood pressure; HR = heart rate. S a l i n e B u p i v a c a i n e C a r b e t a p e n t a n e C a r a m i p h e n were evaluated by using two-way ANOVA followed by pairwise Tukey's HSD test. 
